These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 25554384)
1. Hypothesis: Activation of rapid signaling by environmental estrogens and epigenetic reprogramming in breast cancer. Treviño LS; Wang Q; Walker CL Reprod Toxicol; 2015 Jul; 54():136-40. PubMed ID: 25554384 [TBL] [Abstract][Full Text] [Related]
2. Molecular pathways: environmental estrogens activate nongenomic signaling to developmentally reprogram the epigenome. Wong RL; Walker CL Clin Cancer Res; 2013 Jul; 19(14):3732-7. PubMed ID: 23549878 [TBL] [Abstract][Full Text] [Related]
3. Evaluating chemical effects on mammary gland development: A critical need in disease prevention. Osborne G; Rudel R; Schwarzman M Reprod Toxicol; 2015 Jul; 54():148-55. PubMed ID: 25091782 [TBL] [Abstract][Full Text] [Related]
4. Environmental exposures, breast development and cancer risk: Through the looking glass of breast cancer prevention. Forman MR; Winn DM; Collman GW; Rizzo J; Birnbaum LS Reprod Toxicol; 2015 Jul; 54():6-10. PubMed ID: 25499721 [TBL] [Abstract][Full Text] [Related]
5. A special issue dedicated to a complex tissue. Fenton SE Reprod Toxicol; 2015 Jul; 54():1-5. PubMed ID: 25986312 [No Abstract] [Full Text] [Related]
6. Advancing research on endocrine disrupting chemicals in breast cancer: Expert panel recommendations. Teitelbaum SL; Belpoggi F; Reinlib L Reprod Toxicol; 2015 Jul; 54():141-7. PubMed ID: 25549947 [TBL] [Abstract][Full Text] [Related]
7. Reprogramming of the Epigenome by MLL1 Links Early-Life Environmental Exposures to Prostate Cancer Risk. Wang Q; Trevino LS; Wong RL; Medvedovic M; Chen J; Ho SM; Shen J; Foulds CE; Coarfa C; O'Malley BW; Shilatifard A; Walker CL Mol Endocrinol; 2016 Aug; 30(8):856-71. PubMed ID: 27219490 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Pathiraja TN; Nayak SR; Xi Y; Jiang S; Garee JP; Edwards DP; Lee AV; Chen J; Shea MJ; Santen RJ; Gannon F; Kangaspeska S; Jelinek J; Issa JP; Richer JK; Elias A; McIlroy M; Young LS; Davidson NE; Schiff R; Li W; Oesterreich S Sci Transl Med; 2014 Mar; 6(229):229ra41. PubMed ID: 24670685 [TBL] [Abstract][Full Text] [Related]
9. [Environmental endocrine disruptors and breast cancer: new risk factors?]. Fénichel P; Brucker-Davis F Gynecol Obstet Fertil; 2008 Oct; 36(10):969-77. PubMed ID: 18805035 [TBL] [Abstract][Full Text] [Related]
10. Sustained reprogramming of the estrogen response after chronic exposure to endocrine disruptors. Patterson AR; Mo X; Shapiro A; Wernke KE; Archer TK; Burd CJ Mol Endocrinol; 2015 Mar; 29(3):384-95. PubMed ID: 25594248 [TBL] [Abstract][Full Text] [Related]
11. Environmental signaling: from environmental estrogens to endocrine-disrupting chemicals and beyond. McLachlan JA Andrology; 2016 Jul; 4(4):684-94. PubMed ID: 27230799 [TBL] [Abstract][Full Text] [Related]
12. 4-tert-Octylphenol stimulates the expression of cathepsins in human breast cancer cells and xenografted breast tumors of a mouse model via an estrogen receptor-mediated signaling pathway. Lee HR; Choi KC Toxicology; 2013 Feb; 304():13-20. PubMed ID: 23219593 [TBL] [Abstract][Full Text] [Related]
13. Xenoestrogens, biotransformation, and differential risks for breast cancer. Rogan E Altern Ther Health Med; 2007; 13(2):S112-21. PubMed ID: 17405688 [No Abstract] [Full Text] [Related]
14. Getting it right: BPA and the difficulty proving environmental cancer risks. Fillon M J Natl Cancer Inst; 2012 May; 104(9):652-5. PubMed ID: 22517989 [No Abstract] [Full Text] [Related]
15. Perfluorinated chemicals, PFOS and PFOA, enhance the estrogenic effects of 17β-estradiol in T47D human breast cancer cells. Sonthithai P; Suriyo T; Thiantanawat A; Watcharasit P; Ruchirawat M; Satayavivad J J Appl Toxicol; 2016 Jun; 36(6):790-801. PubMed ID: 26234195 [TBL] [Abstract][Full Text] [Related]
16. Epigenomic reprogramming of the developing reproductive tract and disease susceptibility in adulthood. Walker CL Birth Defects Res A Clin Mol Teratol; 2011 Aug; 91(8):666-71. PubMed ID: 21656660 [TBL] [Abstract][Full Text] [Related]
17. Exposures to synthetic estrogens at different times during the life, and their effect on breast cancer risk. Hilakivi-Clarke L; de Assis S; Warri A J Mammary Gland Biol Neoplasia; 2013 Mar; 18(1):25-42. PubMed ID: 23392570 [TBL] [Abstract][Full Text] [Related]
18. Actions of estrogens and endocrine disrupting chemicals on human prostate stem/progenitor cells and prostate cancer risk. Hu WY; Shi GB; Hu DP; Nelles JL; Prins GS Mol Cell Endocrinol; 2012 May; 354(1-2):63-73. PubMed ID: 21914459 [TBL] [Abstract][Full Text] [Related]
19. Endocrine disruption of the epigenome: a breast cancer link. Knower KC; To SQ; Leung YK; Ho SM; Clyne CD Endocr Relat Cancer; 2014 Apr; 21(2):T33-55. PubMed ID: 24532474 [TBL] [Abstract][Full Text] [Related]
20. California Breast Cancer Prevention Initiatives: Setting a research agenda for prevention. Sutton P; Kavanaugh-Lynch MH; Plumb M; Yen IH; Sarantis H; Thomsen CL; Campleman S; Galpern E; Dickenson C; Woodruff TJ Reprod Toxicol; 2015 Jul; 54():11-8. PubMed ID: 25277312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]